AnalystsBrian ChengBrian Cheng's Stock Forecasts
AnalystsBrian Cheng
Sectors:
Industries:
Analyst Ranking
Bottom 5%
#4788 out of 4986 analysts
Average Return
-10.02%
Win Rate
42%23 out of 55
Risk vs Reward
Poor
Good
Brian Cheng's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Protagonist Therapeutics IncPTGX | +170.97% | $17.19 | $46.58 | 2023-09-25 - 2024-09-24 | Strong Buy |
Sierra Oncology IncSRRA | +143.75% | $22.56 | $54.99 | 2021-09-27 - 2022-06-30 | Strong Buy |
Sierra Oncology IncSRRA | +136.11% | $23.29 | $54.99 | 2021-11-30 - 2022-06-30 | Strong Buy |
Clovis Oncology IncCLVSQ | +70.11% | $0.27 | $0.08 | 2022-11-09 - 2022-12-20 | Strong Sell |
Gossamer Bio IncGOSS | +53.24% | $2.16 | $1.01 | 2022-12-07 - 2023-12-06 | Strong Sell |
Brian Cheng Analyst Color
Get additional color on Brian Cheng's coverage of popular stocks
Brian Cheng's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Immunovant IncIMVT | 3 | Strong Buy | $37.00 | +149.66% | Maintains | 8 days ago |
Immunome IncIMNM | 3 | Strong Buy | $22.00 | +119.56% | Maintains | 13 days ago |
Blueprint Medicines CorpBPMC | 3 | Hold | $129.00 | -0.36% | Downgrades | 3 months ago |
Iteos Therapeutics IncITOS | 4 | Hold | $8.00 | -21.03% | Downgrades | 3 months ago |
Cg Oncology IncCGON | 1 | Strong Buy | $41.00 | +60.41% | Initiates Coverage On | 4 months ago |
Protagonist Therapeutics IncPTGX | 5 | Strong Buy | $57.00 | +1.33% | Maintains | 6 months ago |
Intellia Therapeutics IncNTLA | 4 | Hold | $13.00 | +26.34% | Downgrades | 6 months ago |
Zymeworks IncZYME | 2 | Strong Buy | $18.00 | +27.66% | Upgrades | 8 months ago |
Xencor IncXNCR | 4 | Strong Buy | $28.00 | +268.91% | Maintains | 9 months ago |
Kyverna Therapeutics IncKYTX | 2 | Strong Buy | $33.00 | N/A | Maintains | a year ago |
Metagenomi IncMGX | 2 | Hold | $6.00 | N/A | Downgrades | a year ago |
Mersana Therapeutics IncMRSN | 3 | Hold | $125.00 | N/A | Upgrades | a year ago |
Allogene Therapeutics IncALLO | 3 | Strong Buy | $8.00 | N/A | Maintains | a year ago |
Editas Medicine IncEDIT | 2 | Hold | $9.00 | N/A | Maintains | a year ago |
Cargo Therapeutics IncCRGX | 1 | Strong Buy | $23.00 | N/A | Initiates Coverage On | 2 years ago |
Roivant Sciences LtdROIV | 6 | Strong Buy | $15.00 | N/A | Maintains | 2 years ago |
Bioatla IncBCAB | 3 | Strong Buy | $14.00 | N/A | Maintains | 2 years ago |
Adicet Bio IncACET | 2 | Hold | $6.00 | N/A | Downgrades | 2 years ago |
Senti Biosciences IncSNTI | 1 | Hold | N/A | N/A | Initiates Coverage On | 3 years ago |
Gossamer Bio IncGOSS | 2 | Strong Sell | N/A | N/A | Downgrades | 3 years ago |
Clovis Oncology IncCLVSQ | 1 | Strong Sell | N/A | N/A | Downgrades | 3 years ago |
Adc Therapeutics SaADCT | 2 | Strong Buy | $5.00 | N/A | Initiates Coverage On | 3 years ago |
Poseida Therapeutics IncPSTX | 1 | Strong Buy | $24.00 | N/A | Initiates Coverage On | 4 years ago |
Sierra Oncology IncSRRA | 2 | Strong Buy | $39.00 | N/A | Maintains | 4 years ago |
Regulus Therapeutics IncRGLS | 2 | Strong Buy | $20.00 | N/A | Initiates Coverage On | 4 years ago |
Arcturus Therapeutics Holdings IncARCT | 2 | Strong Buy | $85.00 | N/A | Maintains | 4 years ago |
Biocryst Pharmaceuticals IncBCRX | 1 | Strong Buy | $21.00 | N/A | Initiates Coverage On | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.